A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Trial Profile

A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Desmoteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAS-4
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 01 Nov 2016 Primary endpoint (Modified Rankin Scale Score (mRS) (Percentage of Participants With mRS Scores 0-2) has not been met, according to results published in the Stroke.
    • 01 Nov 2016 Results of the study including post hoc pooled analysis of the concomitant DIAS-3, DIAS-4, and DIAS-J trials published in the Stroke.
    • 08 Oct 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top